Dr. Katelyn Mae Atkins, MD

Dr. Atkins practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Atkins' NPI, 1528470739, was assigned on May 21, 2014. Dr. Atkins graduated from OHSU School of Medicine in 2014. Dr. Atkins holds California license A162728.

Dr. Atkins' primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Atkins' primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Atkins practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Atkins' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Atkins is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Atkins' licenses on file in 3 states: California, Oregon and Massachusetts.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation and pancreatic cancer radiation among the conditions Dr. Atkins treats.

CMS data shows 1,577 Medicare services from Dr. Atkins across 16 procedure codes in 2024, for 123 Medicare patients. Medicare paid $134,847 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 123 Medicare patients who saw Dr. Atkins in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Atkins' median patient age at 75, with 49% women.

In 2024, Dr. Atkins wrote 63 Medicare Part D claims for 18 patients. 84% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $78 in total drug cost. In 2022, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Atkins for performance year 2024, reported as part of a group. Dr. Atkins accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Atkins as offering telehealth.

Dmand AI links 59 papers to Dr. Atkins, published from 2008 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Coronary Vessels. Dr. Atkins has published most often in Int J Radiat Oncol Biol Phys. Dr. Atkins' most frequent co-authors are Raymond H. Mak, MD, Mitchell Kamrava, MD and Elizabeth H. Baldini, MD, MPH.

Dmand AI links Dr. Atkins to 1 clinical trial. Conditions studied include Cardiotoxicity and Drug-Related Side Effects and Adverse Reactions.

CMS Open Payments shows 4 general payments to Dr. Atkins from 2 drug and device companies from 2020 to 2025. Travel and lodging make up the largest share, 77% of the total. Siemens Medical Solutions USA, Inc. paid the most, $384.

Dmand AI lists 1 award for Dr. Atkins.

Dr. Atkins graduated from OHSU School of Medicine in 2014.

Dr. Atkins is in network with 11 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.